TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
ABBV

AbbVie Inc

Healthcare · Drug Manufacturers - General

265.20$ +0.3% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Balance Sheet

AbbVie Inc (ABBV) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 135,134 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ABBV
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
136,221 134,711 148,874 141,937 143,422 135,161 136,165 137,182 133,898 133,960 136,463 135,134
33,224 33,002 38,871 33,816 27,785 25,582 27,675 29,261 28,539 29,062 33,529 33,669
13,287 12,814 18,067 13,130 7,257 5,524 5,175 6,467 5,629 5,229 9,391 6,569
13,290 12,816 18,069 13,157 7,285 5,555 5,176 6,467 5,671 5,257 9,391 6,569
11,412 11,155 11,949 11,724 11,472 10,919 12,477 12,637 12,769 12,589 12,479 13,824
3,981 4,099 4,245 4,218 4,450 4,181 4,526 4,960 4,938 4,951 5,049 5,127
4,934
32,091 32,293 33,426 33,386 35,295 34,956 35,285 35,638 35,626 35,640 35,570 35,519
58,603 55,610 62,225 60,243 66,646 60,068 58,489 57,031 54,315 52,641 50,873 49,139
124,092 124,314 140,827 135,116 137,351 131,797 134,703 137,320 136,497 137,188 143,075 141,003
34,773 37,841 41,522 41,915 43,062 38,749 36,403 39,767 39,391 43,289 42,100 41,642
5,115 7,191 10,196 12,586 12,570 6,804 5,362 7,522 5,772 8,555 8,326 8,341
29,570 3,688 31,258 29,296 30,398 31,910 30,959 31,832 33,362 34,422 33,610 33,173
55,631 52,194 63,805 58,048 58,509 60,340 64,527 62,959 62,971 58,941 64,532 62,481
12,129 10,397 8,047 6,821 6,071 3,364 1,462 -138 -2,599 -3,228 -6,612 -5,935
933 -1,000 -2,384 -3,768 -4,964 -7,900 -9,527 -11,503 -14,234 -15,493 -17,872 -17,333
1,771 1,772 1,773 1,771 1,772 1,773 1,772 1,772 1,772 1,774 1,774 1,771

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?